New assay enables high-resolution spatial visualization of
protein interactions, unlocking functional insights within complex
tissues
MINNEAPOLIS, April 24,
2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH), a global provider of cutting-edge life science tools, today
announced an Early Access Program for its latest advancement in
spatial biology: a powerful new assay for in situ detection of
protein proximity. Built upon Advanced Cell Diagnostics RNAscope™
technology, this next-generation assay is designed to reveal
functional interactions between proteins within intact tissues,
delivering a spatial solution to explore how molecular signaling
shapes disease processes — offering a truly integrated spatial
multiomic view.
"This new protein proximity assay opens the door to seeing
functional interactions between proteins and not merely their
presence in a tissue," said Dr. Matt
McManus, President of Bio-Techne's Diagnostics & Spatial
Biology Segment. "It's a powerful step forward in understanding the
dynamic interplay within tissues that drives biology and
disease."
Conventional methods for studying molecular interactions in
tissues that separately measure proteins and RNA risk losing
spatial fidelity, while bulk proximity assays provide no
localization data. Bio-Techne's proximity detection technology
addresses these gaps with a clear visual signal at subcellular
resolution, built to be compatible with the RNAscope™ Multiomic LS
workflow on BOND RX. This capability is particularly valuable for
research areas where context matters — such as assessing immune
checkpoint dynamics, investigating bispecific antibodies and
studying protein interactions at synaptic junctions.
The Early Access Program is available to select institutions and
researchers interested in incorporating spatial protein proximity
capabilities into their workflows. Proof-of-concept data and case
studies will be shared at the 2025 American Association for
Cancer Research (AACR) annual meeting, presented by
Bio-Techne's scientific team.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With hundreds of thousands of products in its
portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has
approximately 3,100 employees worldwide. For more information on
Bio-Techne and its brands, please visit
http://www.bio-techne.com or follow the Company on social
media at Facebook, LinkedIn, Twitter or YouTube.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-early-access-program-for-next-generation-spatial-protein-proximity-detection-302436484.html
SOURCE Bio-Techne Corporation
